- Home
- BJRI vs BCAX Comparison
BJRI vs BCAX Comparison
Compare BJRI & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJRI
- BCAX
- Stock Information
- Founded
- BJRI 1978
- BCAX 2018
- Country
- BJRI United States
- BCAX United States
- Employees
- BJRI N/A
- BCAX N/A
- Industry
- BJRI Restaurants
- BCAX
- Sector
- BJRI Consumer Discretionary
- BCAX
- Exchange
- BJRI Nasdaq
- BCAX NYSE
- Market Cap
- BJRI 714.3M
- BCAX 670.9M
- IPO Year
- BJRI 1996
- BCAX 2024
- Fundamental
- Price
- BJRI $39.10
- BCAX $12.97
- Analyst Decision
- BJRI Hold
- BCAX Buy
- Analyst Count
- BJRI 5
- BCAX 7
- Target Price
- BJRI $38.25
- BCAX $29.67
- AVG Volume (30 Days)
- BJRI 554.4K
- BCAX 586.0K
- Earning Date
- BJRI 05-01-2025
- BCAX 05-20-2025
- Dividend Yield
- BJRI N/A
- BCAX N/A
- EPS Growth
- BJRI N/A
- BCAX N/A
- EPS
- BJRI 0.95
- BCAX N/A
- Revenue
- BJRI $1,367,941,000.00
- BCAX N/A
- Revenue This Year
- BJRI $5.50
- BCAX N/A
- Revenue Next Year
- BJRI $3.28
- BCAX N/A
- P/E Ratio
- BJRI $40.91
- BCAX N/A
- Revenue Growth
- BJRI 2.91
- BCAX N/A
- 52 Week Low
- BJRI $27.61
- BCAX $8.91
- 52 Week High
- BJRI $41.72
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- BJRI 68.61
- BCAX N/A
- Support Level
- BJRI $37.05
- BCAX N/A
- Resistance Level
- BJRI $39.35
- BCAX N/A
- Average True Range (ATR)
- BJRI 1.32
- BCAX 0.00
- MACD
- BJRI 0.69
- BCAX 0.00
- Stochastic Oscillator
- BJRI 96.51
- BCAX 0.00
About BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.